Recurrent Melanoma Clinical Trial
Official title:
A Phase II Study of Imatinib Mesylate (STI571;NSC#716051:IND 61135) in Patients With Inoperable AJCC Stage III or IV Melanoma Harboring Somatic Alterations of C-KIT
This phase II trial is studying how well imatinib mesylate works in treating patients with stage III or stage IV melanoma that cannot be removed by surgery. Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 30 |
Est. completion date | October 2014 |
Est. primary completion date | December 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically or cytologically confirmed inoperable stage III or IV melanoma that began on acral skin or mucosa - Patients with cutaneous melanoma that began on sun exposed sites of the skin and whose pathology demonstrates signs of sun damage (solar elastosis) involving the skin surrounding their primary melanoma are eligible - Must have sufficient tumor tissue available for FISH and DNA sequencing - Patients must have either a true amplification of 4q12 or a detectable mutation of c-KIT - If no banked tumor tissue is available, or if the available banked tumor tissue is insufficient for the necessary testing, then a repeat biopsy procedure will be required to collect the necessary tumor sample - Measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria - No known untreated brain or epidural metastases - Brain metastases that have been treated and deemed stable are allowed - ECOG performance status (PS) 0-2 OR Karnofsky PS 60-100% - Life expectancy greater than 3 months - WBC = 3,000/mm³ - ANC = 1,500/mm³ - Platelet count = 100,000/mm³ - Bilirubin = 1.5 times upper limit of normal (ULN) - Patients with unexplained hyperbilirubinemia that is clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert's syndrome) may be eligible - AST and ALT = 2.5 times ULN (5 times ULN if hepatic metastases are present) - Creatinine = 1.5 times ULN - PT and PTT = 1.5 times ULN - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception before and during study participation - No history of allergic reactions attributed to compounds of similar chemical or biological composition to imatinib mesylate - No concurrent uncontrolled illness including, but not limited to, any of the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable anginapectoris - Cardiac arrhythmia resulting in hemodynamic instability - Intestinal malabsorption disorders - Psychiatric illness or social situations that would limit study compliance - Recovered to grade 1 from all prior therapies with the exception of alopecia - At least 2 weeks since prior radiotherapy (= 3,000 cGy to fields including substantial marrow) - At least 2 weeks since prior isolated limb infusion or perfusion (must have evidence of progression despite this therapy) - At least 2 weeks since prior chemotherapy - No more than 2 prior chemotherapy regimen for metastatic melanoma - Prior therapies with vaccines, targeted agents not believed to affect the kit proteins, cytokines, interferon-a, or intratumoral injections will NOT be considered prior therapy unless administered with a chemotherapy drug - No prior therapy with an inhibitor of the kit protein - No other concurrent investigational agents - No other concurrent anticancer agents or therapies - No concurrent antiretroviral therapy for HIV-positive patients - No concurrent inhibitors of CYP3A4, including any of the following: - Fluconazole, itraconazole, ketoconazole, macrolide antibiotics (azithromycin, clarithromycin, erythromycin, troleandomycin),midazolam, nifedipine, verapamil, diltiazem, terfenadine, cyclosporine and cisapride - Herbal extracts and tinctures with CYP3A4 inhibitory activity, including the following: - Hydrastis canadensis (goldenseal), Hypericum perforatum (St. John's wort),Uncaria tomentosa (cat's claw), Echinacea angustifolia roots, Trifolium pratense(wild cherry), Matricaria, chamomilla (chamomile), Glycyrrhiza glabra (licorice), dillapiol, hypericin, and naringenin - No concurrent inducers of CYP3A4, including any of the following: - Carbamazepine, phenobarbital, phenytoin, and rifampin |
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | University of California at Los Angeles (UCLA ) | Los Angeles | California |
United States | Mount Sinai Medical Center CCOP | Miami Beach | Florida |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Mount Sinai Medical Center | New York | New York |
United States | New York University Langone Medical Center | New York | New York |
United States | Weill Medical College of Cornell University | New York | New York |
United States | Good Samaritan Medical Center | West Palm Beach | Florida |
United States | Palm Beach Cancer Institute-Main Office | West Palm Beach | Florida |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Objective Response Rate | Response will be evaluated in this study using the new international criteria proposed by the RECIST Committee. A Simon two-stage minimax design will be employed. | Every 6 weeks for the first 3 courses and then every 12 weeks thereafter | No |
Secondary | Time to Progression | Progression will be evaluated in this study using the new international criteria proposed by the RECIST Committee. Time to progression will be estimated using the Kaplan-Meier method. | Time from the treatment start to the date of disease progression | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02224781 -
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma
|
Phase 3 | |
Completed |
NCT01886235 -
Intravital Microscopy for Identifying Tumor Vessels in Patients With Stage IA-IV Melanoma That is Being Removed by Surgery
|
N/A | |
Completed |
NCT00553306 -
Laboratory-Treated T Cells and Aldesleukin After Cyclophosphamide in Treating Patients With Stage IV Melanoma
|
Phase 1/Phase 2 | |
Completed |
NCT00121225 -
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
|
Phase 2 | |
Completed |
NCT00019448 -
Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT01961115 -
Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma
|
Phase 2 | |
Completed |
NCT01748747 -
Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery
|
Early Phase 1 | |
Terminated |
NCT01316692 -
Aurora A Kinase Inhibitor MLN8237 in Treating Patients With Unresectable Stage III-IV Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT01120275 -
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma
|
Phase 2 | |
Terminated |
NCT01166126 -
Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Completed |
NCT00288041 -
Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma
|
Phase 2 | |
Completed |
NCT00074308 -
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers
|
Phase 1/Phase 2 | |
Completed |
NCT00072163 -
Temozolomide and Thalidomide in Treating Patients With Brain Metastases Secondary to Melanoma
|
Phase 2 | |
Completed |
NCT01989559 -
Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery
|
Phase 1 | |
Completed |
NCT00026143 -
Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Malignant Melanoma
|
Phase 2 | |
Completed |
NCT00006243 -
Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma
|
N/A | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Completed |
NCT01703507 -
Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
|
Phase 1 |